Discover 318 paid clinical trials in Mississippi. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Mississippi provides diverse clinical research opportunities, opening doors for healthy volunteers interested in paid studies, as well as people with specific health conditions to contribute to medical research. Research hubs in Jackson, Gulfport, and Hattiesburg are actively recruiting, granting participants access to innovative treatments and comprehensive care.
Filter
1
Filter results
Results: 318
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
for
Moderately to Severely Active Ulcerative Colitis
Location: Providence RI, Lebanon NH, North Massapequa NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06588855
Phase3, Recruiting
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Boston MA, Providence RI, North Massapequa NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase3, Recruiting
Featured
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for
Non Small Cell Lung Cancer
Location: Levis, Greenfield Park, Montreal, Brampton,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT04928846
Phase3, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Providence RI, North Worcester MA, Lebanon NH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819891
Phase3, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Boston MA, Needham MA, New Haven CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Providence RI, New Haven CT, Lebanon NH, Bay Shore NY,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase2, Recruiting
Featured
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Nashua NH, Stamford CT, Morristown NJ, Philadelphia PA,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Location: Burlington MA, East Greenwich RI, Carmel NY,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06318169
Phase3, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Morristown NJ, Philadelphia PA, Franklin VA, Miami FL,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: New Bedford MA, New Haven CT, Manhasset NY, New York NY,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
for
NASH - Nonalcoholic Steatohepatitis,
Location: South Dartmouth MA, New Haven CT, Manhasset NY,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06528314
Phase3, Recruiting
Active & Responsive
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
for
Alzheimer Disease
Location: North Dartmouth MA, Boston MA, Belmont MA,
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sex: All
Age: 55 - 70+
Code: NCT06585787
Phase3, Recruiting
Active & Responsive
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
for
Bipolar Disorder Type I With Mania
Location: New Haven CT, Staten Island NY, Marlton NJ,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18 - 65
Code: NCT06929273
Phase3, Recruiting
Active & Responsive
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
for
Ulcerative Colitis
Location: Great Neck NY, Chesapeake VA, Lansdowne Town Center VA,
Sponsor: Gilead Sciences
Sex: All
Age: 18 - 70+
Code: NCT06029972
Phase2, Recruiting
Active & Responsive
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
for
Sickle Cell Disease
Location: The Bronx NY, Philadelphia PA, Easton PA, Baltimore MD,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 12 - 70+
Code: NCT06439082
Phase3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Quebec, Chicoutimi, Mineola NY, New York NY,